On August 18, Twist Bioscience Corp rose 5.07% in regular trading, trading at $124.45/share, with turnover of $99.76 million. The stock rebounded following a prior session pullback, driven by continued positive sentiment from its fiscal Q3 earnings report released on August 3.

The company reported Q3 revenue of $118.4 million, beating the consensus estimate of $114.5 million, marking its 14th consecutive quarter of growth with 23% year-over-year expansion. More notably, management issued Q4 revenue guidance of $123 million to $124 million, significantly exceeding the FactSet estimate of $117.4 million. The CEO indicated the company expects to reach adjusted EBITDA breakeven this quarter.

As a core DNA synthesis supplier in the AI drug discovery value chain, Twist Bioscience is deeply tied to growing demand from AI-driven protein engineering and drug candidate screening. The company recently completed a $300 million equity offering underwritten by top-tier investment banks to expand production capacity. Analysts maintain a consensus buy rating with a mean price target of $87.56, while the stock has gained approximately 295% year-to-date.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)